Ozempic and Heart Attack Recovery: A New Hope for Patients
Weight-loss drugs like Ozempic, initially developed for type 2 diabetes, are showing promise in improving heart attack recovery and reducing the risk of life-threatening complications, according to new research from the University of Bristol and University College London (UCL). The findings, published in Nature Communications on March 3, 2026, suggest a potential new therapeutic approach for patients following a heart attack.
GLP-1 Drugs and Cardiovascular Health: What the Research Shows
Previous studies have demonstrated that GLP-1 (glucagon-like peptide-1) receptor agonists can lower the risk of serious heart problems, irrespective of a patient’s other health conditions or the amount of weight lost. The University of Bristol researchers sought to understand the mechanisms behind these benefits.
The study focuses on a complication known as “no-reflow,” where tiny blood vessels within the heart muscle remain narrowed even after the main artery is cleared during emergency treatment. This narrowing restricts blood flow to parts of the heart tissue, increasing the risk of death or hospital admission for heart failure within a year of a heart attack. Researchers found that GLP-1 drugs may prevent this problem.
How GLP-1 Drugs Improve Blood Flow
Building on previous work identifying that small contractile cells called pericytes constrict coronary capillaries during ischemia (lack of oxygen-rich blood), the team investigated how GLP-1 might reverse these blockages. Their experiments revealed that GLP-1 drugs activate potassium channels, leading to the relaxation of pericytes and the reopening of blocked microvessels.
“In nearly half of all heart attack patients, tiny blood vessels within the heart muscle remain narrowed, even after the main artery is cleared during emergency medical treatment,” explains Dr. Svetlana Mastitskaya, Senior Lecturer in Cardiovascular Regenerative Medicine at Bristol Medical School and lead author of the study. “Our latest findings are surprising in that we found that GLP-1 drugs could prevent this problem.”
Brain-Gut-Heart Connection
The research, also highlighted by AOL, identified a biological brain-gut-heart signaling pathway. When GLP-1 hormone is released in the gut or administered as a drug, it sends a signal to the brain, which then signals the heart to activate the potassium channels in pericytes, ultimately improving blood flow.
Current Status and Future Implications
While these findings are promising, it’s essential to note that the results are currently preclinical. No official protocols currently recommend Ozempic or similar drugs immediately following a heart attack. In France, semaglutide is currently reserved for type 2 diabetes, and Wegovy for severe obesity, under medical supervision.
Professor David Attwell, Professor of Physiology at UCL and co-leader of the study, stated, “With a growing number of similar GLP-1 drugs now in clinical practice, for conditions ranging from type 2 diabetes and obesity to kidney disease, our results highlight the potential for these existing drugs to be repurposed to treat the risk of ‘no-reflow’ in heart attack patients, offering a potentially life-saving solution.”
Understanding Myocardial Infarction
Myocardial infarction, commonly known as a heart attack, involves the destruction of heart muscle due to a blockage in a coronary artery. Risk factors include genetics, age, overweight and obesity, type 2 diabetes, hypertension, and high cholesterol. Cardiovascular diseases remain the leading cause of death globally, accounting for approximately 17.9 million deaths annually.